{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:47:24Z","timestamp":1792684044720,"version":"4.5.0"},"reference-count":0,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glioblastoma (GBM) harboring EGFRvIII represents a biologically distinct and highly aggressive tumor subset characterized by aberrant receptor signaling, marked intratumoral heterogeneity, and profound immune remodeling. Rather than acting as a constitutively active truncated receptor, EGFRvIII represents a structurally rewired EGFR variant whose altered extracellular architecture, receptor assembly, and trafficking promote ligand-independent signaling and signaling plasticity, thereby supporting tumor proliferation, stemness, invasion, and angiogenesis. Beyond tumor-intrinsic effects, EGFRvIII also contributes to the formation of a spatially heterogeneous, myeloid-dominant and immunosuppressive tumor microenvironment, characterized by myeloid-cell expansion, impaired T cell effector function, and mesenchymal-like tumor\u2013immune plasticity. Despite extensive therapeutic efforts including tyrosine kinase inhibitors, monoclonal antibodies, vaccines, immune checkpoint blockade, and EGFRvIII-targeted CAR-T cell strategies, durable clinical efficacy remains limited by the interplay of antigen heterogeneity, adaptive signaling, clonal evolution, and microenvironmental immunosuppression. Taken together, EGFRvIII can be viewed as a structural and evolutionary regulator that links receptor rewiring and signaling plasticity with immune ecosystem remodeling and therapeutic resistance,\u00a0underscoring the need for integrated strategies that target both tumor cell-intrinsic signaling and the suppressive microenvironment.<\/jats:p>","DOI":"10.1093\/neuonc\/noag266","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:40:54Z","timestamp":1792669254000},"source":"Crossref","is-referenced-by-count":0,"title":["EGFRvIII-Positive Glioblastoma: Structural Rewiring, Immune Microenvironmental Remodeling, and Therapeutic Resistance"],"prefix":"10.1093","author":[{"given":"Haoyuan","family":"Ye","sequence":"first","affiliation":[{"name":"Capital Medical University Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, , No.10 Xitoutiao You\u2019anmenwai Fengtai District, Beijing 100069, PR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Qiu","sequence":"additional","affiliation":[{"name":"Capital Medical University Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, , No.10 Xitoutiao You\u2019anmenwai Fengtai District, Beijing 100069, PR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangge","family":"Zhu","sequence":"additional","affiliation":[{"name":"Capital Medical University Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, , No.10 Xitoutiao You\u2019anmenwai Fengtai District, Beijing 100069, PR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Quan","sequence":"additional","affiliation":[{"name":"Institute of Animal Husbandry and Veterinary Medicine, Beijing Academy of Agriculture and Forestry Sciences , No. 9 Shuguang Garden Middle Road Haidian District, Beijing, 100097, PR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Su","sequence":"additional","affiliation":[{"name":"Capital Medical University Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, , No.10 Xitoutiao You\u2019anmenwai Fengtai District, Beijing 100069, PR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renxi","family":"Wang","sequence":"additional","affiliation":[{"name":"Capital Medical University Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, , No.10 Xitoutiao You\u2019anmenwai Fengtai District, Beijing 100069, PR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Fu","sequence":"additional","affiliation":[{"name":"Capital Medical University Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, , No.10 Xitoutiao You\u2019anmenwai Fengtai District, Beijing 100069, PR","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,22]]},"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag266\/72365253\/noag266.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag266\/72365253\/noag266.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:37:17Z","timestamp":1792683437000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article\/doi\/10.1093\/neuonc\/noag266\/8979451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag266","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"article-number":"noag266"}}